Small Molecules

14 May 2019 Allegro Ophthalmics Announces Positive Results of Ex-U.S. Proof-of-Concept Trial with Integrin Inhibitor ALG-1007 for Dry Eye Disease
13 May 2019 Polyphor temporarily halts enrollment in the Phase III studies of murepavadin for the treatment of patients with nosocomial pneumonia
13 May 2019 Minerva Neurosciences Announces Positive Top Line Results in Phase 2b Clinical Trial With Seltorexant (MIN-202) in Treatment of Depressed Patients With an Inadequate Response to SSRIs and SNRIs
13 May 2019 ORIC Pharmaceuticals Announces Initiation of Phase 1b Study with ORIC-101 in Patients with Cancer
13 May 2019 Celgene Corporation Announces POMALYST® Granted Breakthrough Therapy Designation from FDA for HIV-Positive and Negative Kaposi Sarcoma
13 May 2019 FLX Bio Highlights Preclinical Atopic Dermatitis and Asthma Data for FLX193 at the American Association of Immunologists (AAI) Annual Meeting 2019
12 May 2019 Positive Phase II Data Further Highlights Clinical Proof of Concept for Evobrutinib, First Oral Bruton's Tyrosine Kinase (BTK) Inhibitor to Report Positive Phase II Clinical Results in MS
12 May 2019 Sunovion and PsychoGenics Announce that SEP-363856 Has Received FDA Breakthrough Therapy Designation for the Treatment of People with Schizophrenia
12 May 2019 Vifor Pharma’s Phase-II AMBER Study Meets Primary Endpoint
10 May 2019 Pooled analyses of the roxadustat global Phase III programme confirmed cardiovascular safety
08 May 2019 Nabriva Therapeutics Announces Submission of Marketing Authorization Application for Lefamulin to Treat Community-Acquired Pneumonia in Adults by European Medicines Agency
08 May 2019 Neuropore Initiates Phase 1 Clinical Trial in Healthy Volunteers with NPT520-34, a Therapeutic Candidate Aimed at Treating Parkinson’s Disease and Amyotrophic Lateral Sclerosis
07 May 2019 Cytokinetics Announces Results of FORTITUDE-ALS, a Phase 2 Clinical Trial of Reldesemtiv in Patients With ALS, Presented at American Academy of Neurology Annual Meeting
07 May 2019 Neuronascent Announces FDA Clearance of IND Application for NNI-362 an Aging Therapy to Treat Alzheimer's Disease
07 May 2019 RedHill Biopharma Submits New Drug Application for Talicia® for H. pylori Infection
07 May 2019 OnKure Announces FDA IND Regulatory Clearance to Start Phase 1 Trials for OKI-179
07 May 2019 Merck’s BELSOMRA® (suvorexant) C-IV Meets Primary Efficacy Endpoint in Phase 3 Trial for the Treatment of Insomnia in People with Mild-to-Moderate Alzheimer’s Disease Dementia
07 May 2019 European Commission Approves LORVIQUA® (lorlatinib) for Certain Adult Patients with Previously-Treated ALK-Positive Advanced Non-Small Cell Lung Cancer
07 May 2019 Viela Bio Presents Pivotal Study Results of Inebilizumab in Patients with Neuromyelitis Optica Spectrum Disorder in a Plenary Session at the American Academy of Neurology Annual Meeting
07 May 2019 Lundbeck to acquire Abide Therapeutics, adding a unique discovery platform and a lead compound in an exploratory phase IIa program for Tourette’s
07 May 2019 FDA approves first treatment for children with Lambert-Eaton myasthenic syndrome, a rare autoimmune disorder
07 May 2019 Genentech Presents Data from the Risdiplam Pivotal FIREFISH and SUNFISH Studies in Spinal Muscular Atrophy at the 2019 AAN Annual Meeting
07 May 2019 SpringWorks Therapeutics Announces Initiation of Phase 1b Clinical Trial of MEK Inhibitor PD-0325901 in Combination with BeiGene’s RAF Dimer Inhibitor Lifirafenib in Advanced or Refractory Solid Tumors
07 May 2019 Calquence Phase III ASCEND trial met primary endpoint at interim analysis in relapsed or refractory chronic lymphocytic leukaemia and will stop early
07 May 2019 Qternmet XR approved in the US for the treatment of type-2 diabetes

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2018 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up